Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $928,950.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.89, for a total value of $928,950.00. Following the transaction, the chief executive officer now owns 575,661 shares in the company, valued at $9,722,914.29. The trade was a 8.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Saurabh Saha also recently made the following trade(s):

• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total transaction of $30,479.04.
• On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.32, for a total transaction of $39,709.44.
• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.80, for a total transaction of $350,839.00.
• On Friday, September 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.53, for a total value of $909,150.00.
• On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.52, for a total value of $2,891,000.00.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $17.04 on Monday. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The firm has a 50-day moving average of $16.09 and a 200-day moving average of $12.42. Centessa Pharmaceuticals plc has a one year low of $5.58 and a one year high of $18.74. The company has a market cap of $1.93 billion, a P/E ratio of -11.14 and a beta of 1.47.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.05. Equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on CNTA shares. Oppenheimer reiterated an “outperform” rating and issued a $14.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. Jefferies Financial Group boosted their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. BMO Capital Markets raised their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. Finally, B. Riley began coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a “buy” rating and a $33.00 price target for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $25.83.

Institutional Trading of Centessa Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. First Light Asset Management LLC bought a new position in Centessa Pharmaceuticals in the 1st quarter valued at $33,923,000. Farallon Capital Management LLC boosted its holdings in shares of Centessa Pharmaceuticals by 438.0% in the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock worth $18,024,000 after buying an additional 1,625,000 shares during the last quarter. Janus Henderson Group PLC bought a new position in Centessa Pharmaceuticals during the third quarter valued at about $20,698,000. Driehaus Capital Management LLC increased its holdings in Centessa Pharmaceuticals by 89.5% during the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock worth $18,891,000 after buying an additional 987,997 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in Centessa Pharmaceuticals by 54.1% during the third quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock worth $43,423,000 after buying an additional 953,659 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.